|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||359.47 g/mol g·mol−1|
|3D model (JSmol)|
Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.